Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.

ABSTRACT:

Background

Patients with schizophrenia often suffer from cognitive deficits and negative symptoms that are poorly responsive to antipsychotics including clozapine. Clozapine-induced sedation can worsen cognition and impair social and occupational functioning.

Objectives

To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine.

Method

A double-blind, placebo-controlled, flexible-dosed 8-week pilot trial was conducted between September 2003 and September 2007, adding modafinil up to 300 mg/d to stabilized schizophrenia outpatients receiving clozapine. Psychopathology, cognition, and wakefulness/fatigue were assessed with standard rating scal

SUBMITTER: Freudenreich O 

PROVIDER: S-EPMC5038350 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature